Cerdulatinib (PRT062070, PRT2070, DMVT-502) is a low molecular weight tyrosine kinase inhibitor SYK / JAK , an oral drug developed for the treatment of hematologic diseases [1] . Cerdulatinib is a multikinase inhibitor with the highest specificity for TYK2 , JAK1 , JAK2, JAK3, FMS and SYK kinases [2] .
| Cerdulatinib | |
|---|---|
 | |
| Chemical compound | |
| IUPAC | 4- (Cyclopropylamino) -2- [4- (4-ethylsulfonylpiperazin-1-yl) anilino] pyrimidine-5-carboxamide |
| Gross formula | C 20 H 27 N 7 O 3 S |
| Cas | |
| PubChem | |
| Route of administration | |
| Oral | |
History
The drug was developed by specialists of the pharmaceutical company Portola pharmaceuticals . Preliminary results of a clinical trial of I and II phases showed the activity of cerdulatinib in patients with CLL and FL [3] . At the same time, there was no activity against DVBCL and mantle cell lymphoma . In September 2018, the FDA granted cerdulatinib the status of an orphan drug for the treatment of T-cell lymphomas [4] .
See also
- Ruxolitinib
- Entospletinib
- Fostamatinib
Notes
- ↑ Delong Liu, Aleksandra Mamorska-Dyga. Syk inhibitors in clinical development for hematological malignancies // Journal of Hematology & Oncology. - 2017-07-28. - T. 10 , no. 1 . - S. 145 . - ISSN 1756-8722 . - DOI : 10.1186 / s13045-017-0512-1 .
- ↑ Greg Coffey, Andreas Betz, Francis DeGuzman, Yvonne Pak, Mayuko Inagaki. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer // The Journal of Pharmacology and Experimental Therapeutics. - 2014-12. - T. 351 , no. 3 . - S. 538-548 . - ISSN 1521-0103 . - DOI : 10.1124 / jpet.114.218164 .
- ↑ Greg P. Coffey, Greg P. Coffey, Andreas Betz, Jiajia Feng, Anjali Pandey. Cerdulatinib pharmacodynamics and relationships to tumor response following oral dosing in patients with relapsed / refractory B-cell malignancies // Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. - 2018-10-17. - ISSN 1078-0432 . - DOI : 10.1158 / 1078-0432.CCR-18-1047 .
- ↑ Investors - News Release - Portola Pharmaceuticals, Inc. (eng.) . phx.corporate-ir.net. Date of appeal October 29, 2018.